Repeated cold stress, an animal model for fibromyalgia, elicits proprioceptor-induced chronic pain with microglial activation in mice.
Wakatsuki, Koji, Kiryu-Seo, Sumiko, Yasui, Masaya et al. · Journal of neuroinflammation · 2024 · DOI
Quick Summary
Researchers used mice exposed to repeated cold stress to study how chronic pain develops, similar to fibromyalgia. They found that sensory nerve cells (proprioceptors) become overactive and trigger immune cells in the nervous system called microglia to become inflamed. When they reduced microglial activity with a drug, the pain improved, suggesting that this immune activation along nerve pathways may be a key driver of long-lasting pain.
Why It Matters
This research identifies a potential shared biological mechanism—proprioceptor hyperactivation triggering microglial inflammation—that could underlie chronic pain in both fibromyalgia and ME/CFS. The finding that blocking microglial activation reduces pain provides a testable therapeutic target that could benefit both conditions. Understanding this mechanism may lead to new treatment approaches for the chronic pain experienced by many ME/CFS patients.
Observed Findings
Repeated cold stress in mice produced long-lasting chronic pain measurable by von Frey test.
ATF3 expression (a marker of neuronal stress) appeared in proprioceptive sensory neurons in the dorsal root ganglia 2 days after cold stress initiation.
Microglial activation and proliferation occurred in the spinal cord within 5-7 days, concentrated along the reflex arc pathway.
ATF3-positive motor neurons projecting to foot muscles were surrounded by activated microglia in the ventral spinal cord.
Pharmalogical suppression of microglia using PLX3397 significantly reduced pain behavior.
Inferred Conclusions
Proprioceptor hyperactivation initiates a cascade of microglial activation along the reflex arc that sustains chronic pain.
Prolonged microglial activation along specific neural pathways may be the key mechanism maintaining chronic pain in this model.
Propriceptor-induced microglial activation may represent a common pathological process shared between fibromyalgia and ME/CFS models.
Microglial suppression is a potentially viable therapeutic strategy for reducing proprioceptor-driven chronic pain.
Remaining Questions
Does this proprioceptor-microglial mechanism operate in human ME/CFS and fibromyalgia patients, or is it unique to the animal model?
What This Study Does Not Prove
This animal study does not prove that proprioceptor-microglial activation is the sole cause of chronic pain in human ME/CFS or fibromyalgia patients. The repeated cold stress model, while useful, may not fully replicate the complex etiology of these conditions in humans. Additionally, findings in mice do not guarantee that the same mechanisms operate identically in human nervous systems or that drugs effective in mice will be safe and effective in patients.
What triggers the initial proprioceptor hyperactivation in humans—is it a primary neuronal defect, an immune trigger, metabolic dysfunction, or something else?
Are there sex differences in proprioceptor sensitivity and microglial responses that might explain variable disease severity and symptom expression?
Which microglial suppression strategies would be safe and effective for long-term therapeutic use in human patients?